Tibet Duo Rui Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Tibet Duorui Pharmaceutical Co., Ltd. (referred to as "Duorui Pharmaceutical") was registered with the Changdu Industrial and Commercial Department on December 22, 2016 and has settled in the Changdu Economic Development Zone in Tibet. The company is mainly engaged in the research and development, production, and sales of chemical pharmaceutical preparations and their raw materials. Since its establishment, the company has focused on product pipeline layout in the perioperative and emergency rescue fields, and has now achieved a strong competitive advantage in the field of plasma substitutes. The company was listed on the Shenzhen Stock Exchange Growth Enterprise Board on September 29, 2021, with a current share capital of 80 million yuan. In the future, the company will focus on plasma substitutes as the main development line, expanding the research and development, production, and sales of raw materials and formulations in characteristic fields such as emergency rescue drugs, children's drugs, and psychiatric drugs; At the same time, the company will actively respond to the national policy of encouraging the development of traditional Chinese medicine, and carry out innovative development of traditional Chinese medicine classic formulas and Tibetan medicine classic formulas, as well as the cultivation of traditional Chinese medicine and Tibetan medicine. In order to achieve the overall strategy and development goals of the company, the company will adhere to the business philosophy of combining imitation and innovation, focusing on characteristics, and steadily developing. Focusing on the field of high-tech barrier generic drugs and improved new drugs, as well as traditional Chinese medicine specialty products, the company will enrich its product pipeline, continuously improve product competitiveness and patient medication experience, and strive to become a leading enterprise in the domestic characteristic segmentation field. |
| Headquarter | Changdu City |
| Establish Date | 12/22/2016 |
| Listed Code | 301075.SZ |
| Listed Date | 9/29/2021 |
| Chairman | Deng Yong. |
| CEO | Deng Yong. |
| Website | www.duoruiyy.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
